Biologics, including TNF-α, IL-17, IL-23, IFNAR1 inhibitors, as well as JAK inhibitors, may represent a new frontier in the treatment of scarring alopecias refractory to the standard of care by modulating key inflammatory pathways. The gene discussed is TNF; the disease is alopecia.